Dato-DXd targets TROP2 on tumor cells, is internalized, and releases the DXd payload that inhibits topoisomerase I to cause DNA breaks and apoptosis (with a bystander effect). DNA topoisomerase I is the intracellular enzymatic payload target, not the antigen used to select cells for killing.